The Spark: Why This Review Now?
Over the last few years, research has confirmed that we ingest and inhale thousands of micronanoplastic (MNP) particles daily. Yet, the scientific community often operates in silos—studies on pulmonary effects are disconnected from those on reproductive failure or neurotoxicity.
This fragmentation led us to a crucial question: Is there a common mechanism linking these disparate adverse outcomes? We realized the scientific landscape required a comprehensive synthesis that connected these isolated "islands" of data, defining MNPs as a systemic, immunity-driven health problem.
The Challenge: Mapping the Immune Highway
The task was colossal. We had to synthesize evidence from human, animal, and in vitro models, covering eight major body systems (nervous, endocrine, respiratory, digestive, and others).
The greatest challenge was reconciling the vast differences in MNP data—particles varied in shape, size, material, and concentration across studies. We needed to identify a universal language of toxicity that could explain why such diverse particles lead to such consistently alarming pathologies.
Our Key Finding: Inflammation is the Common Thread
Our analysis revealed that MNPs are not passive, inert particles; they are active disruptors of cellular processes. The core mechanism of their harm is a cascading immune dysfunction, primarily manifesting through two pathways:
-
Oxidative Stress: MNPs induce excessive production of free radicals, damaging cells across all organs.
-
Immune Dysregulation: The particles trigger persistent, low-grade inflammation that can contribute to neuroinflammation, endocrine disruption, and other chronic illnesses.
In essence, we found that the immune system acts as the highway through which MNPs exert their systemic effects across the entire body.
The Research Agenda: What Happens Next?
Our review is not an endpoint; it is a roadmap. It’s a clear call to action for the scientific community. To effectively combat this global threat, standardization is essential. We urge researchers to:
-
Standardize Protocols: Adopt unified testing protocols and MNP characterization metrics to make results truly comparable globally.
-
Focus on Nanoplastics: Increase research on the smallest fraction—nanoplastics—as their capacity to cross biological barriers (like the blood-brain and placental barriers) presents the most significant threat.
-
Transition to Clinical Relevance: Develop clinical intervention and prevention strategies to protect human health from this pervasive environmental danger.